PL393601A1 - Kryształy D bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek - Google Patents

Kryształy D bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek

Info

Publication number
PL393601A1
PL393601A1 PL393601A PL39360102A PL393601A1 PL 393601 A1 PL393601 A1 PL 393601A1 PL 393601 A PL393601 A PL 393601A PL 39360102 A PL39360102 A PL 39360102A PL 393601 A1 PL393601 A1 PL 393601A1
Authority
PL
Poland
Prior art keywords
preparation
crystals
composition containing
solid oral
pharmaceutical composition
Prior art date
Application number
PL393601A
Other languages
English (en)
Other versions
PL219565B1 (pl
Inventor
Takuji Bando
Satoshi Aoki
Junichi Kawasaki
Makoto Ishigami
Youichi Tanigichi
Tsuyoshi Yabuuchi
Kiyoshi Fujimoto
Yoshihiro Nishioka
Noriyuki Kobayashi
Tsutomu Fujimura
Masanori Takahashi
Kaoru Abe
Tomonori Nakagawa
Koichi Shinhama
Naoto Utsumi
Michiaki Tominaga
Yoshihiro Oi
Shohei Yamada
Kenij Tomikawa
Original Assignee
Otsuka Pharmaceutical Co, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36049773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL393601(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CA 2379005 external-priority patent/CA2379005A1/en
Application filed by Otsuka Pharmaceutical Co, Ltd. filed Critical Otsuka Pharmaceutical Co, Ltd.
Publication of PL393601A1 publication Critical patent/PL393601A1/pl
Publication of PL219565B1 publication Critical patent/PL219565B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL393601A 2001-09-25 2002-09-25 Kryształy D bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy D bezwodnego aripiprazolu PL219565B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001290645 2001-09-25
JP2001348276 2001-11-14
CA 2379005 CA2379005A1 (en) 2001-09-25 2002-03-27 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof

Publications (2)

Publication Number Publication Date
PL393601A1 true PL393601A1 (pl) 2011-04-26
PL219565B1 PL219565B1 (pl) 2015-05-29

Family

ID=36049773

Family Applications (7)

Application Number Title Priority Date Filing Date
PL393603A PL221536B1 (pl) 2001-09-25 2002-09-25 Kryształy C bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393607A PL393607A1 (pl) 2001-09-25 2002-09-25 Sposób wytwarzania granulek farmaceutycznego stałego preparat doustnego i sposób wytwarzania farmaceutycznego stałego preparatu doustnego oraz farmaceutyczny stały preparat doustny
PL393596A PL393596A1 (pl) 2001-09-25 2002-09-25 Kryształy G bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek
PL393598A PL221521B1 (pl) 2001-09-25 2002-09-25 Kryształy F bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393608A PL219564B1 (pl) 2001-09-25 2002-09-25 Kryształy E bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy E bezwodnego aripiprazolu
PL417178A PL230869B1 (pl) 2001-09-25 2002-09-25 Hydrat A aripiprazolu i sposób jego wytwarzania
PL393601A PL219565B1 (pl) 2001-09-25 2002-09-25 Kryształy D bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy D bezwodnego aripiprazolu

Family Applications Before (6)

Application Number Title Priority Date Filing Date
PL393603A PL221536B1 (pl) 2001-09-25 2002-09-25 Kryształy C bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393607A PL393607A1 (pl) 2001-09-25 2002-09-25 Sposób wytwarzania granulek farmaceutycznego stałego preparat doustnego i sposób wytwarzania farmaceutycznego stałego preparatu doustnego oraz farmaceutyczny stały preparat doustny
PL393596A PL393596A1 (pl) 2001-09-25 2002-09-25 Kryształy G bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek
PL393598A PL221521B1 (pl) 2001-09-25 2002-09-25 Kryształy F bezwodnego aripiprazolu i sposób ich wytwarzania oraz zawierające je kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny
PL393608A PL219564B1 (pl) 2001-09-25 2002-09-25 Kryształy E bezwodnego aripiprazolu, sposób ich wytwarzania, kompozycja farmaceutyczna i farmaceutyczny stały preparat doustny zawierające kryształy E bezwodnego aripiprazolu
PL417178A PL230869B1 (pl) 2001-09-25 2002-09-25 Hydrat A aripiprazolu i sposób jego wytwarzania

Country Status (21)

Country Link
EP (1) EP3081216A1 (pl)
KR (2) KR100490222B1 (pl)
CN (12) CN103288727B (pl)
AR (3) AR073111A2 (pl)
CA (1) CA2713466C (pl)
CL (1) CL2010000405A1 (pl)
CY (4) CY1110070T1 (pl)
DK (1) DK1925308T3 (pl)
ES (1) ES2596354T3 (pl)
HK (5) HK1203059A1 (pl)
IL (3) IL204707A (pl)
LT (1) LT1925308T (pl)
MY (1) MY138669A (pl)
NO (1) NO337844B1 (pl)
PE (1) PE20030445A1 (pl)
PH (1) PH12014500782A1 (pl)
PL (7) PL221536B1 (pl)
PT (1) PT1925308T (pl)
RU (1) RU2279429C2 (pl)
SI (1) SI1927357T1 (pl)
TW (2) TWI332839B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
KR102128883B1 (ko) * 2019-10-02 2020-07-01 (주)삼화바이오팜 고순도 아리피프라졸의 신규 결정형 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
JP3638447B2 (ja) * 1998-09-10 2005-04-13 積水ハウス株式会社 笠木取付金具および笠木取付構造
GB9930061D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Quinolone compounds for use in treating viral infections
IL150651A0 (en) * 2000-01-20 2003-02-12 Eisai Co Ltd Nitrogen-containing cyclic compound and pharmaceutical compositions containing the same
US20020076437A1 (en) * 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4197088B2 (ja) 2000-06-05 2008-12-17 電気化学工業株式会社 低密度かつ低ガス透過性六方晶窒化硼素焼結体及びその製造方法
JP2002193915A (ja) * 2000-12-28 2002-07-10 Otsuka Pharmaceut Co Ltd ベンゼンスルフォナート化合物

Also Published As

Publication number Publication date
CN104306337A (zh) 2015-01-28
PL393603A1 (pl) 2011-04-26
NO337844B1 (no) 2016-06-27
KR100530731B1 (ko) 2005-11-23
HK1136961A1 (en) 2010-07-16
PL221521B1 (pl) 2016-04-29
HK1092808A1 (en) 2007-02-16
CY1110070T1 (el) 2015-01-14
HK1196128A1 (zh) 2014-12-05
CN104945321A (zh) 2015-09-30
AR073111A2 (es) 2010-10-13
RU2004126636A (ru) 2006-02-10
HK1215397A1 (zh) 2016-08-26
CN103751093A (zh) 2014-04-30
PL393607A1 (pl) 2011-03-14
IL225902A0 (en) 2013-06-27
HK1136960A1 (en) 2010-07-16
CN103751119A (zh) 2014-04-30
KR20040053372A (ko) 2004-06-23
PL393608A1 (pl) 2011-03-14
IL204707A0 (en) 2010-11-30
HK1136959A1 (en) 2010-07-16
PL221536B1 (pl) 2016-04-29
CN103755632B (zh) 2016-06-29
CN103191118A (zh) 2013-07-10
IL234770A0 (en) 2014-11-30
MY138669A (en) 2009-07-31
HK1223043A1 (zh) 2017-07-21
HK1203060A1 (en) 2015-10-16
AR077635A2 (es) 2011-09-14
RU2279429C2 (ru) 2006-07-10
PE20030445A1 (es) 2003-07-26
HK1203059A1 (en) 2015-10-16
PL393598A1 (pl) 2011-04-26
CN103751118A (zh) 2014-04-30
TW200942238A (en) 2009-10-16
PH12014500782A1 (en) 2018-09-10
AR087544A2 (es) 2014-04-03
PL219565B1 (pl) 2015-05-29
SI1927357T1 (sl) 2010-09-30
KR20030060871A (ko) 2003-07-16
HK1136958A1 (en) 2010-07-16
CN103288727A (zh) 2013-09-11
DK1925308T3 (en) 2016-12-12
CY1110244T1 (el) 2015-01-14
EP3081216A1 (en) 2016-10-19
ES2596354T3 (es) 2017-01-09
TWI332839B (en) 2010-11-11
IL204707A (en) 2016-06-30
HK1129889A1 (en) 2009-12-11
PL219564B1 (pl) 2015-05-29
TWI318572B (en) 2009-12-21
PL417178A1 (pl) 2016-07-04
KR100490222B1 (ko) 2005-05-18
CN103755632A (zh) 2014-04-30
HK1129891A1 (en) 2009-12-11
CN105267151A (zh) 2016-01-27
HK1187048A1 (zh) 2014-03-28
CN103288727B (zh) 2016-04-27
PL230869B1 (pl) 2018-12-31
CY1110212T1 (el) 2015-01-14
CL2010000405A1 (es) 2010-10-15
CY1110208T1 (el) 2015-01-14
CN102579446A (zh) 2012-07-18
LT1925308T (lt) 2016-11-10
NO20141193L (no) 2003-01-17
HK1210468A1 (en) 2016-04-22
PT1925308T (pt) 2016-10-24
CN105832677A (zh) 2016-08-10
CA2713466A1 (en) 2003-04-03
CA2713466C (en) 2012-01-03
CN104306374A (zh) 2015-01-28
PL393596A1 (pl) 2011-04-26

Similar Documents

Publication Publication Date Title
IL166058A0 (en) Novel thiophenylglycoside derivatives methods for production thereof medicaments comprising said compounds and use thereof
HUP0402588A3 (en) Quinazoline derivatives, pharmaceutical compositions containing them, process for producing them and their use
NO20031694D0 (no) Krystallinsk monohydrat, fremgangsmåte for fremstilling derav og anvendelsederav til fremstilling av et medikament
NO20033244D0 (no) Farmasöytisk sammensetning med redusert tendens for legemiddelkrystallisasjon
ZA200409862B (en) Benzofused heteroaryl derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
ATE367152T1 (de) Herstellungsverfahren für niedrig dosierte pharmazeutische zusammensetzung
DE60304599D1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
AU2003241671A8 (en) Controlled-release drug composition
IL175127A0 (en) Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
IL174507A0 (en) Pharmaceutical compositions comprising malonamide derivatives for decreasing sebum production
AU2003231920A8 (en) Antiinfectve compounds, process for their preparation and pharmaceutical compositions containing them
IS7424A (is) Oxasólídínónafleiður, aðferðir til að framleiða þær og lyfjablöndur sem innihalda þær
IL175023A0 (en) Method for producing tiotropium salts, tiotropium salts and pharmaceutical formulations, containing the same
PL393598A1 (pl) Kryształy F bezwodnego aripiprazolu i sposób ich wytwarzania oraz kompozycja farmaceutyczna je zawierająca, farmaceutyczny stały preparat doustny i sposób jego wytwarzania oraz sposób wytwarzania granulek
PT1603550E (pt) Composição farmacêutica que compreende ácido 5-metil-2-2¿- (cloro-6¿-fluoroanilino)fenilacético
IL170315A (en) Cycloalkyl-substituted alkanoic acid derivatives, pharmaceutical compositions and use thereof
ATE248171T1 (de) Isoindoloindolon-derivate, verfahren zu ihrer herstellung und die enthaltende pharmazeutische zusammensetzungen
NO20043633L (no) Oral doseringsform for kontrollert medikamentfrigivning
EG24369A (en) New isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them
SI1565467T1 (sl) Novi derivati antagonista vitronektin receptorja, postopek za pripravo le teh njihova uporaba kot zdravila in farmacevtskega sestavka, ki jih vsebuje
SG134980A1 (en) Oral pharmaceutical compositions containing non-steroidal anti- inflammatory drugs and method for preparing the same
EP1626697A4 (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION WITH LITHIUM CARBONATE
ITTO20020672A1 (it) Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid
SG110170A1 (en) New benzoindoline compounds, a process for their preparation and pharmaceutical compositions containing them